LANREOTIDE | LANREOTIDE | ATC H01CB03
HORMONES SOMATOSTATIN ANALOG LONG-TERM TREATMENT OF ACROMEGALIC PATIENTS INHIBITOR OF VARIOUS ENDOCRINE, NEUROENDOCRINE, EXOCRINE AND PARACRINE FUNCTIONS REDUCTION OF GH AND/OR IGF-1 LEVELS | SUBCUTANEOUS | Cmax 5.7 NANOMOLAR Tmax 9.5 HOUR F 78.4 PERCENT (120 MILLIGRAM) VD 13 LITER (65 KILOGRAM) PPB 81 PERCENT Cl 23.7 LITER / HOUR HT 636 HOUR | SOMATOSTATIN RECEPTORS (SSTR) 2 AND 5 REDUCED BINDING AFFINITY FOR HUMAN SSTR1, 3, AND 4 | SOMATOSTATIN RECEPTOR 2 AGONIST CHEMBL1804 SOMATOSTATIN RECEPTOR 2 P30874 SOMATOSTATIN RECEPTOR TYPE 2 HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 PEPTIDE SHORT PEPTIDE SOMATOSTATIN RECEPTOR | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |